


## **Motivation**


How best to validate and standardize AO and OCT performance?

- ISO OCT standard is limited
- No clinical gold standards to compare to
  - OCT is three-dimensional and not directly relatable to standard fundus imaging

FDA

- OCT angiography employs fundamentally different technological characteristics than dye angiography
- Unprecedented and exceptional capabilities in AO and OCT
  Other functional biomarkers (e.g., phase-based)
  - AO provides uniquely high spatial resolution, coupled with dynamic and personalized imaging





































eqm	enta	τιοι	n		
search Article				L OPTICS EXPRESS 6205	N
omedical Optic	EXPRESS		and the second	a a T	
und antices	d as have			has been a	See. See
ancement				hy image	
A LUCY 2 P	A, BHAVE	A J. ANT	ONY, MAT	THEW H. LEE, <sup>1</sup> KAWA, <sup>2</sup> GADI	a
STEIN,2 JOEI	S. SCHUM	IAN. <sup>2</sup> AND	RAHIL GA	BNAVI <sup>1</sup>	
esearch, Level 22/60					Cital Cita
ment of Optishalmole F, USA	gj, NYU Longon	t Eye Centre, N	ew York Universit	ity School of Medicine, Ne	
	PSNR	SSIM	MS-SSIM	MSE	
Healthy	TOM				
Raw	26.82±0.67	0.62±0.04	0.79±0.02	136.67±22.43	
		0.62±0.04 0.74±0.04	0.79±0.02 0.88±0.02	136.67±22.43 51.53±17.29	
Raw	26.82±0.67				
Raw BM3D	26.82±0.67 31.17±1.27	0.74±0.04	$0.88 \pm 0.02$	51.53±17.29	
Raw BM3D DD-CDWT	26.82±0.67 31.17±1.27 31.21±1.19	0.74±0.04 0.75±0.04	0.88±0.02 0.89±0.02	51.53±17.29 51.22±15.92	
Raw BM3D DD-CDWT CNN-WGAN	26.82±0.67 31.17±1.27 31.21±1.19 31.83±1.21	0.74±0.04 0.75±0.04 0.77±0.03	0.88±0.02 0.89±0.02 0.92±0.01	51.53±17.29 51.22±15.92 44.52±14.34	
Raw BM3D DD-CDWT CNN-WGAN CNN-MSE	26.82±0.67 31.17±1.27 31.21±1.19 31.83±1.21 32.28±1.27	0.74±0.04 0.75±0.04 0.77±0.03 0.78±0.03	0.88±0.02 0.89±0.02 0.92±0.01 0.92±0.01	51.53±17.29 51.22±15.92 44.52±14.34 40.28±13.44	Fig. 1. CTI may time planament where equally CPUIII DOCTS and compared before many time planament where equally CPUIII DOCTS and compared before many time (Fig. 1). The real of equations of the second second second second second second second second seco
Raw BM3D DD-CDWT CNN-WGAN CNN-MSE Glaucoma	26.82±0.67 31.17±1.27 31.21±1.19 31.83±1.21 32.28±1.27 PSNR	0.74±0.04 0.75±0.04 0.77±0.03 0.78±0.03 SSIM	0.88±0.02 0.89±0.02 0.92±0.01 0.92±0.01 MS-SSIM	51.53±17.29 51.22±15.92 44.52±14.34 48.28±13.44 MSE	
Raw BM3D DD-CDWT CNN-WGAN CNN-MSE Glaucoma Raw	26.82±0.67 31.17±1.27 31.21±1.19 31.83±1.21 32.28±1.27 PSNR 25.46±0.67	0.74±0.04 0.75±0.04 0.77±0.03 0.78±0.03 SSIM 0.58±0.04	0.88±0.02 0.89±0.02 0.92±0.01 0.92±0.01 MS-SSIM 0.76±0.02	51.53±17.29 51.22±15.92 44.52±14.34 44.28±13.44 MSE 188.32±52.53	and corresponding 6-frame averaged image (b). The result of post-processing of CNN-MSE (c), CNN-WGAN (d), BMID (c), and DD-CDWT (f). Three recented in
Raw BM3D DD-CDWT CNN-WGAN CNN-MSE Glaucema Raw BM3D	26.82±0.67 31.17±1.27 31.21±1.19 31.83±1.21 32.28±1.27 PSNR 25.46±0.67 29.12±1.12	0.74±0.04 0.75±0.04 0.77±0.03 0.78±0.03 SSIM 0.58±0.04 0.74±0.03	0.88±0.02 0.89±0.02 0.92±0.01 0.92±0.01 MS-SSIM 0.76±0.02 0.88±0.03	51.53±17.29 51.22±15.92 44.52±14.34 40.28±13.44 MSE 188.32±52.53 83.34±44.76	and corresponding 6-frame averaged image (b). The result of post-processing of CNN-MSE (c), CNN-WGAN (d), BMID (c), and DD-CDWT (f). Three recented in









## **Summary**

FDA

16

- A number of non-clinical physical tools (phantoms and model eyes) have been developed for AO and OCT imaging, mostly in prototype form
- Community consensus needed to identify most important data to obtain with physical tools
  - Imaging performance figures of merit
  - Measurement accuracy
  - System calibration during longitudinal studies
  - Post-processing traceability
- Software-based synthetic image usage in AO and OCT is quite nascent; data augmentation has potential to enhance training of AI/deep learning algorithms